Parkinson's Disease News and Research

Latest Parkinson's Disease News and Research

FDA finalizes new rule on donor eligibility for human tissues and cells

FDA today published a final rule establishing donor eligibility criteria for donors of human cells, tissues, and cellular and tissue-based products (HCT/Ps) to help prevent the transmission of communicable disease when these products are transplanted.

20 May 2004

Closer to understanding the function of a protein linked to an inherited form of the movement disorder dystonia

The protein, torsinA, is defective in patients with DYT1 dystonia, an inherited condition that causes uncontrollable movements in the limbs and torso. Learning what torsinA does could be an important step toward developing a treatment for the disorder.

19 May 2004

Centre for Life opens with the UK’s first two human embryonic stem cell lines

The UK’s first two human embryonic stem cell lines, developed separately by researchers at King’s College London and the Centre for Life in Newcastle, are to be deposited in the UK Stem Cell Bank. The deposit coincides with the official opening of the Bank by Health Minister, Lord Warner, today (Wednesday 19 May 2004).

19 May 2004

Scientists move closer toward treatment for degenerative diseases

Scientists at McGill University's Faculty of Medicine have discovered a key step that will provide new targets for treatments of many degenerative diseases such as Alzheimer's, Cystic Fibrosis and Diabetes.

17 May 2004

Research into placebo effect among Parkinson’s patients

Parkinson’s disease patients who thought they had received a transplant of human neurons into their brains—but who actually hadn’t—reported an improved quality of life one year later.

14 May 2004

Britannia Pharmaceuticals’ partner receives FDA approval for Parkinson’s disease treatment

Britannia Pharmaceuticals Limited announced today that U.S.-based Bertek Pharmaceuticals Inc., the branded subsidiary of Mylan Laboratories Inc has received approval from the Food and Drug Administration for APOKYN (apomorphine hydrochloride injection).

13 May 2004

Indicators identify shingles patients who have an increased risk of developing persistent pain

Researchers have recently confirmed a set of indicators that, alone and in combination, identify shingles patients who have an increased risk of developing persistent pain after the shingles rash heals. Results and implications of their study will be presented in the May 11 issue of Neurology, the scientific journal of the American Academy of Neurology.

10 May 2004

Ritalin drug used to treat hyperactive children boosts the potency of Parkinson's drug levodopa

A well-known drug used to treat hyperactive children boosts the potency of another drug that reduces Parkinson's disease symptoms, an Oregon Health & Science University study has found.

6 May 2004

Mylan announces FDA approval of Parkinson’s disease drug

The FDA approval clears the way for Bertek to market APOKYN and provides a new therapy for “off” episodes, one of the most debilitating aspects suffered by patients with Parkinson’s disease.

5 May 2004

Tooth cells may help treat Parkinson's disease

Cells derived from the inside of a tooth might someday prove an effective way to treat the brains of people suffering from Parkinson's disease.

4 May 2004

Transplanted bone-marrow cells could regenerate nerve cells in the brain

Findings of a preliminary study in this week's issue of THE LANCET suggest that transplanted adult bone-marrow cells could regenerate nerve cells in the brains of human stem-cell recipients. These early findings, if confirmed in future research, have implications for the treatment of neurodegenerative disorders such as Parkinson's disease.

29 Apr 2004

Antiepileptic drug Levetiracetam may help patients with Parkinson's disease

In patients with Parkinson's disease, the antiepileptic drug levetiracetam (Keppra(R)) reduced the involuntary movements (dyskinesia) associated with levodopa, the medication most commonly used to treat Parkinson's disease, according to a study presented today at the 56th annual meeting of the American Academy of Neurology.

29 Apr 2004

Greater severity of depressive symptoms correlates with increased risk of stroke among whites

Greater severity of depressive symptoms correlates with increased risk of stroke among whites, according to research that will be presented at the American Academy of Neurology 56th Annual Meeting in San Francisco, Calif., April 24 – May 1, 2004.

28 Apr 2004

PET imaging has recently been shown to aid in the diagnosis of particular neurological syndromes associated with cancer

PET imaging has been shown to improve detection of a variety of cancers, and earlier tests have suggested this technique may be useful in identifying small tumors in patients with paraneoplastic neurological disorders. But PET imaging is not yet widely available, and clear indicators of clinically meaningful outcomes using PET are essential to warrant use with this patient population.

28 Apr 2004

A popular supplement, coenzyme Q10 (CoQ10), may help prevent migraine

Migraine patients who took 100 mg three times a day of CoQ10—which acts as the body’s energy producer—had fewer attacks in three months than those who took a placebo. The participants taking CoQ10 also had fewer days with a headache and fewer days with nausea.

28 Apr 2004

Results look promising in Alzheimer’s gene therapy trial

Surgical placement of genetically modified tissue directly into the brains of patients with Alzheimer’s disease, an experimental approach to delaying brain cell loss associated with the disease, leads to increased metabolic activity in the brain, with cells apparently responding to the insertion of growth factor-producing grafts

28 Apr 2004

Study shows MIRAPEX(R) (pramipexole) relieves patients with restless legs syndrome

Results from a large-scale, randomized, double-blind study show MIRAPEX(R) (pramipexole) provides rapid relief in patients with restless legs syndrome (RLS).

28 Apr 2004

New teatment for intractable low blood pressure

Patients are generally pleased with a new Mayo Clinic drug treatment for a common form of impaired nerve transmission that causes dizziness and fainting when patients change position from lying down to standing up, and most want to continue using it.

28 Apr 2004

Blood pressure drug helps delay ischemic brain damage in stroke patients

A drug used to lower blood pressure can help stop or delay the progress of further ischemic brain lesions in stroke patients according to research that will be presented at the American Academy of Neurology 56th Annual Meeting in San Francisco, Calif., April 24 – May 1, 2004.

27 Apr 2004

Apolipoprotein E (APOE) gene may increase the risk of Parkinson’s disease

One variant of the apolipoprotein E (APOE) gene may increase the risk of Parkinson’s disease, according to an analysis of research that will be presented at the American Academy of Neurology 56th Annual Meeting in San Francisco, Calif., April 24 – May 1, 2004.

27 Apr 2004